2030 Immunization Pharmaceutical Companies 
pharmaphorum
JUNE 8, 2021
At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. million in 2030.
pharmaphorum
MARCH 10, 2022
Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030. Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MARCH 7, 2024
Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?
pharmaphorum
JUNE 1, 2022
According to the World Health Organization, the world will need more than 40 million new doctors, nurses, frontline healthcare workers, and various other healthcare professionals by 2030. This has not escaped the notice of pharmaceutical companies looking to educate patients on topics, with which they may not have the most health literacy.
Pharmaceutical Business Review
DECEMBER 26, 2024
This also stands as a commitment from our side to support the 2030 vision ofSaudi Arabiathrough localising biopharmaceutical products in the Kingdom.” “Tabuk is a leading pharmaceutical company in the MENA region and is a great partner to ensure patients inSaudi Arabiahave the best access to BAT2206.”
Expert insights. Personalized for you.
105 
Let's personalize your content